Combination TKI and Anti-EGF Antibody Regimens for NSCLC
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-small-cell lung cancer (NSCLC) driven by deregulated Human Epidermal Growth Factor Receptor (HER/EGFR) face challenges due to acquired resistance to EGFR-targeted therapies, with limited therapeutic alternatives for patients who develop resistance or do not respond to tyrosine kinase inhibitors (TKIs).
Innovation Solution
A method involving the combination of a tyrosine kinase inhibitor (TKI) with active EGF Pathway Immunization (EGF PTI) or anti-EGF antibodies, administered in a flexible regimen to inhibit the EGF-EGFR pathway, with the TKI given continuously in doses ranging from 10 to 150 mg and EGF PTI or antibodies given thrice, twice, or once a week, or monthly, to prevent resistance and enhance therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EGFR-targeted therapies (tyrosine kinase inhibitors) are used to treat NSCLC, then initial treatment response is improved, but acquired resistance develops over time
Solution Approach 1:
The patent combines EGFR-targeted therapies with anti-EGF antibodies or active EGF pathway immunization to create a dual-mechanism treatment approach. This merging of different therapeutic modalities aims to simultaneously block EGFR signaling through TKIs while also neutralizing EGF ligand through antibodies or inducing active immunity, thereby preventing resistance development and extending treatment duration.
Solution Approach 2:
The patent employs anti-EGF antibodies or active immunization to preemptively block the EGF ligand before it can activate EGFR, even in the presence of TKI therapy. This preliminary anti-action targets the upstream ligand to prevent activation of the receptor, creating a layered defense against resistance mechanisms that might otherwise bypass TKI inhibition.
2Productivity
If standard cytotoxic chemotherapies are used, then broad anti-tumor activity is achieved, but side effects increase and effectiveness decreases
Solution Approach 1:
The patent employs targeted agents that specifically modulate proteins essential for oncogenesis and maintenance of cancer, particularly enzymes driving uncontrolled growth, angiogenesis, invasiveness, and metastasis. This local quality approach concentrates therapeutic activity at the molecular level within cancer cells while sparing normal tissues, thereby reducing side effects while maintaining or improving anti-tumor effectiveness.
Solution Approach 2:
The patent transitions from nonselective chemotherapy to targeted therapy by changing the selectivity parameter of the treatment. Targeted agents are designed to be selective in their effects by modulating the activity of specific proteins necessary and essential for oncogenesis, creating a differential activity profile that spares normal tissues while effectively attacking cancer cells.
3Duration of action of moving object
If combination therapy with TKI and anti-EGF antibodies is used, then resistance development is delayed, but treatment complexity increases
Solution Approach 1:
The patent employs flexible dosing regimens for the combination therapy, with anti-EGF antibodies or immunization administered periodically (e.g., every 2-4 weeks) while TKIs are given continuously or intermittently. This periodic action allows for sustained therapeutic effect while managing treatment complexity through structured, repeating cycles rather than continuous complex interventions.
Data Source
AI summary
A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The anti-EGF antibodies can be produced by active immunization or provided passively by the administration of antibodies that are anti-EGF. The method comprises TKI administered according to a continuous regimen based on an average daily dose in the range of 10 to 150 mg and the mAb is co-administered either actively or passively according to a dosing regimen achieving a therapeutic effective amount repeated thrice, twice or once a week, once in two weeks, once in three weeks or at least once monthly.